Study design for laboratory developed tests (LDT) and in vitro diagnostics (IVD) can make or break product and business success. This top-down description of how to pick the right study design was delivered at the 5th Clinical Affairs & Regulatory Approvals For Diagnostics, October 27-29, 2014, in Alexandria, Virginia.
One size does not fit all unique study management challenges for diagnostic ...Lyssa Friedman
When partnering with a CRO, diagnostic company needs are different from those of pharmaceutical and device companies. This presentation was delivered at Outsourcing in Clinical Trials West Coast 2015, February 3-4, Burlingame, California.
Emerging diagnostic technologies proving the clinical application through g...Lyssa Friedman
Next Generation Sequencing is an exciting new technology for diagnostics companies. But is it right for all products and for all companies? This presentation was delivered via Webinar for a IVD audience for Q1 Productions, March 25, 2014.
Elizabeth Mansfield, PhD, discusses the FDA’s approach to regulation
of in vitro diagnostic tests.
Part of Dx2010, a workshop at MaRS focused on best practices and regulatory considerations for developing gene-based diagnostic and prognostic tests.
Medical Device Clinical Studies and Protocol DesignMichael Swit
August 17, 2006 presentation to the IVT Medical Device Conference, focusing on the following relative to medical devices:
* Standards of Approval – What the Protocol Targets
* Key Considerations in Designing Clinical Studies
* Practical Lessons in Clinical Trial Design & Execution
Get Your Development Program Started on the Right FootBrook White, PMP
You think you have a potential pharmaceutical or biotechnology product based on animal or in vitro data—what is the next step? Two documents you need at an early stage are the Target Product Profile (TPP) which defines expectations for your potential medicine and an Integrated Product Development Plan (IPDP) which describes the activities required through approval of your marketing application.
How can one regulatory program simultaneously benefit both blockbuster drugs and rare or neglected diseases? How can your company leverage the opportunities afforded by this program? This presentation walks you through the how’s and why’s of the FDA’s Priority Review Voucher program.
One size does not fit all unique study management challenges for diagnostic ...Lyssa Friedman
When partnering with a CRO, diagnostic company needs are different from those of pharmaceutical and device companies. This presentation was delivered at Outsourcing in Clinical Trials West Coast 2015, February 3-4, Burlingame, California.
Emerging diagnostic technologies proving the clinical application through g...Lyssa Friedman
Next Generation Sequencing is an exciting new technology for diagnostics companies. But is it right for all products and for all companies? This presentation was delivered via Webinar for a IVD audience for Q1 Productions, March 25, 2014.
Elizabeth Mansfield, PhD, discusses the FDA’s approach to regulation
of in vitro diagnostic tests.
Part of Dx2010, a workshop at MaRS focused on best practices and regulatory considerations for developing gene-based diagnostic and prognostic tests.
Medical Device Clinical Studies and Protocol DesignMichael Swit
August 17, 2006 presentation to the IVT Medical Device Conference, focusing on the following relative to medical devices:
* Standards of Approval – What the Protocol Targets
* Key Considerations in Designing Clinical Studies
* Practical Lessons in Clinical Trial Design & Execution
Get Your Development Program Started on the Right FootBrook White, PMP
You think you have a potential pharmaceutical or biotechnology product based on animal or in vitro data—what is the next step? Two documents you need at an early stage are the Target Product Profile (TPP) which defines expectations for your potential medicine and an Integrated Product Development Plan (IPDP) which describes the activities required through approval of your marketing application.
How can one regulatory program simultaneously benefit both blockbuster drugs and rare or neglected diseases? How can your company leverage the opportunities afforded by this program? This presentation walks you through the how’s and why’s of the FDA’s Priority Review Voucher program.
FDA 2013 Clinical Investigator Training Course: Issues in Clinical Trials Des...MedicReS
FDA 2013 Clinical Investigator Training Course: Issues in Clinical Trials Designs for Devices
Owen Faris, Ph.D.,Deputy Director, Division of Cardiovascular Devices, Office of Device Evaluation, CDRH, FDA
Investigation Device Exemptions (IDEs) for Early Feasibility Medical Device C...BostonBiomedical
Marybeth Gamber, Senior Regulatory Affairs Principal in Consulting Services presented at the Opal Events Medical Devices Summit West on June 25, 2015 in San Jose, CA. The attached presentation entitled, “Investigation Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies,” will focused on the FDA Early Feasibility Study (EFS) program. The intention of the EFS program is for devices that are early in their development lifecycle for which preclinical test methods are either not available or adequate to provide information to advance the device development process. Ms. Gamber discussed the background of the IDE process, the creation of the EFS program and guidance, along with the key steps and considerations to consider when pursuing this path, including lessons learned from on early interactions with the FDA in this program.
Clinical trials that are needed for efficacy & safety evidence of Medical devices include feasibility (pilot) and Pivotal trials. An extended battery of preclinical trials are also needed for high risk devices.
Considerations for the Next Wave of COVID-19 DevelopmentMedpace
What did we learn from the first wave of COVID-specific studies that can be applied to those studies that will follow? Medpace has gathered some of its medical and operational team experts who have been on the front-line in designing and conducting trials for SARS-CoV-2 to answer some frequently asked questions, trends they see emerging and considerations for future development.
COVID-19 Product Development and Clinical Trials: Considerations from Europea...Medpace
Join experts from Medpace’s regulatory and operational teams in this webinar as they provide insights and considerations on how to accelerate product development for COVID-19 during different stages
Globalization of Clinical Trials: Mutual acceptance of Medical Device dataAnnet Visscher
Technologies and regulatory standards facilitate clinical trial globalization and mutual acceptance of clinical trial data. Changes in trial execution, however, are not 1:1 reflected in foreign data acceptance. Factors such as ethnic and local requirements seem to outweigh the benefits.
TCD MENA was a Main Sponsor of Armed Forces College of Medicine GCP Workshop that was held on 27,28th FEB 2017. Dr. Hanaa Abdel-Maguid (Managing Director - TCD MENA) was an instructor in the GCP Workshop where she presented a session entitled "Sponsor/CRO responsibilties.
TCD MENA CRO is an affiliate of TCD Global headquartered in South Africa, providing end-to-end clinical research services: Regulatory Affairs, Clinical Operations, Project Management, Pharmacovigilance, Data Management, Biostatistics & Medical Writing.
TCD MENA Team has extensive clinical research experience for managing global clinical trials with sites in Egypt and MENA region; also experienced in managing bioequivalence studies accepted by WHO, FDA & EU. The team has worked in different therapeutic areas including Oncology, Hepatology, Internal Medicine, Gynecology, chronic diseases with strong relationships with KOLs across Egypt & MENA region.
TCD MENA Team understands the needs of sponsors in a time when there are significant economic constraints globally. Part of our mission will be to convert these sponsor needs into innovative solutions to support R&D objectives in terms of Quality, Time & Cost flexibility.
TCD MENA looks forward to demonstrate its capabilities and commitment to achieve your goals as the start of a long term solid partnership with your respectful organization. TCD Global will remain responsive to global trends and changing customer needs.
FDA 2013 Clinical Investigator Training Course: Issues in Clinical Trials Des...MedicReS
FDA 2013 Clinical Investigator Training Course: Issues in Clinical Trials Designs for Devices
Owen Faris, Ph.D.,Deputy Director, Division of Cardiovascular Devices, Office of Device Evaluation, CDRH, FDA
Investigation Device Exemptions (IDEs) for Early Feasibility Medical Device C...BostonBiomedical
Marybeth Gamber, Senior Regulatory Affairs Principal in Consulting Services presented at the Opal Events Medical Devices Summit West on June 25, 2015 in San Jose, CA. The attached presentation entitled, “Investigation Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies,” will focused on the FDA Early Feasibility Study (EFS) program. The intention of the EFS program is for devices that are early in their development lifecycle for which preclinical test methods are either not available or adequate to provide information to advance the device development process. Ms. Gamber discussed the background of the IDE process, the creation of the EFS program and guidance, along with the key steps and considerations to consider when pursuing this path, including lessons learned from on early interactions with the FDA in this program.
Clinical trials that are needed for efficacy & safety evidence of Medical devices include feasibility (pilot) and Pivotal trials. An extended battery of preclinical trials are also needed for high risk devices.
Considerations for the Next Wave of COVID-19 DevelopmentMedpace
What did we learn from the first wave of COVID-specific studies that can be applied to those studies that will follow? Medpace has gathered some of its medical and operational team experts who have been on the front-line in designing and conducting trials for SARS-CoV-2 to answer some frequently asked questions, trends they see emerging and considerations for future development.
COVID-19 Product Development and Clinical Trials: Considerations from Europea...Medpace
Join experts from Medpace’s regulatory and operational teams in this webinar as they provide insights and considerations on how to accelerate product development for COVID-19 during different stages
Globalization of Clinical Trials: Mutual acceptance of Medical Device dataAnnet Visscher
Technologies and regulatory standards facilitate clinical trial globalization and mutual acceptance of clinical trial data. Changes in trial execution, however, are not 1:1 reflected in foreign data acceptance. Factors such as ethnic and local requirements seem to outweigh the benefits.
TCD MENA was a Main Sponsor of Armed Forces College of Medicine GCP Workshop that was held on 27,28th FEB 2017. Dr. Hanaa Abdel-Maguid (Managing Director - TCD MENA) was an instructor in the GCP Workshop where she presented a session entitled "Sponsor/CRO responsibilties.
TCD MENA CRO is an affiliate of TCD Global headquartered in South Africa, providing end-to-end clinical research services: Regulatory Affairs, Clinical Operations, Project Management, Pharmacovigilance, Data Management, Biostatistics & Medical Writing.
TCD MENA Team has extensive clinical research experience for managing global clinical trials with sites in Egypt and MENA region; also experienced in managing bioequivalence studies accepted by WHO, FDA & EU. The team has worked in different therapeutic areas including Oncology, Hepatology, Internal Medicine, Gynecology, chronic diseases with strong relationships with KOLs across Egypt & MENA region.
TCD MENA Team understands the needs of sponsors in a time when there are significant economic constraints globally. Part of our mission will be to convert these sponsor needs into innovative solutions to support R&D objectives in terms of Quality, Time & Cost flexibility.
TCD MENA looks forward to demonstrate its capabilities and commitment to achieve your goals as the start of a long term solid partnership with your respectful organization. TCD Global will remain responsive to global trends and changing customer needs.
IMS Health Clinical Trial Optimization SolutionsQuintilesIMS
IMS Health's Linda T. Drumright, general manager, Clinical Trial Optimization Solutions presents at the 3rd Annual Patient Recruitment & Retention Summit 2014 - San Francisco, CA
Adoptive Design: Optimizing Clinical Trial Strategies for Precision MedicineClinosolIndia
Clinical trials play a pivotal role in advancing medical research and ensuring the efficacy of new treatments. In the context of precision medicine, where therapies are tailored to individual characteristics, adaptive design emerges as a powerful strategy to optimize clinical trial outcomes. This approach deviates from traditional fixed trial designs, allowing for modifications based on accumulating data, thus enhancing efficiency, flexibility, and the likelihood of success in precision medicine endeavors.
IDSC is an interdisciplinary group of 40 ex-pharma leaders averaging 25-years of big-pharma, biotech, and academic experience. Our clients come to us for drug discovery and drug development interim leadership, consulting, fully integrated collaborations, due diligence, molecular modeling, and outsourcing management. Because we are a fully integrated drug discovery, preclinical development, and clinical development partner, we help our biotech, VC, academic, and pharma clients get from early discovery to IND filing and through phase I clinical trials in all major therapeutic areas and on to NDA in antibacterials, CNS, and oncology.
How early is too early for pharmaceutical market insights and product forecasts. A discussion on pipeline product research during early product development
Similar to The power of study design 2014 10-27 (20)
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Light House Retreats: Plant Medicine Retreat Europe
The power of study design 2014 10-27
1. The Power of Study Design
5th Clinical Affairs & Regulatory Approvals For Diagnostics
October 27-29 2014 – Alexandria, VA
Lyssa Friedman
1October 27, 2014 Lyssa Friedman
2. October 27, 2014 Lyssa Friedman 2
Golden Gate National Recreation Area
3. Key Points
Study design:
Things to consider
FDA regulation of LDTs:
Keep doing what you’re doing well
Publication success
Case Study
Successes and lessons learned
October 27, 2014 Lyssa Friedman 3
4. Study goals = company goals
Successful product launch
On time
In scope
Revenues
Reimbursement
October 27, 2014 Lyssa Friedman 4
5. Start with the goal and work backward
October 27, 2014 Lyssa Friedman 5
Business goals
Patient population
Regulatory requirements
Test requirements
Study design
Publication strategy
6. • Business strategy
• Unmet clinical need
• Target customer(s)
• Market and market size
• Messaging strategy
• Geography
– States (CLIA)
– US/global
• Reimbursement plan
• Revenue goals
October 27, 2014 Lyssa Friedman 6
Business goals
7. • Disease/health condition
• Unmet clinical need
• Gold standard
• Current landscape
– Diagnostic tools
– Best practices
– Clinical guidelines
October 27, 2014 Lyssa Friedman 7
Patient population
8. • Risk classification
• LDT regulated by CLIA
• IVD
– 510(k)
– PMA
– de novo
– HDE
• Companion diagnostic
• Kit manufacturing
October 27, 2014 Lyssa Friedman 8
Regulatory requirements
9. • Performance characteristics
– Sensitivity
– Specificity
– Negative predictive value
– Positive predictive value
• Test results
– Continuous score
– Discrete result
• Clinical significance
October 27, 2014 Lyssa Friedman 9
Test
requirements
12. Health Economics
• Payer modeling
• Verify unmet need
• Verify market
October 27, 2014 Lyssa Friedman 12
Study
design
Why commercialize? What business benefit?
13. Health Economics:
Consider the payer
Market
Payer landscape
Target price
Revenue targets
Product positioning
COGS
October 27, 2014 Lyssa Friedman 13
14. Analytic Validation
• Verify assay robustness
• Commercial readiness
• CLIA registration
October 27, 2014 Lyssa Friedman 14
Study
design
Will the assay work? Is it submission-ready?
15. Analytic Validation
Consider the customer
Variability in handling at point of collection
Interruptions in current practice flow
Requisition form design
Patient report design
October 27, 2014 Lyssa Friedman 15
16. Clinical Validation
Diagnostic Clinical Performance
• Establish test performance
• Gold standard
• Intended use
• Support
• FDA submission
• CLIA registration (some states)
• Publication plan
• Physician adoption
• Guideline acceptance
• Payer adoption
October 27, 2014 Lyssa Friedman 16
Study
design
Will the data be published? Will physicians order the test?
Will it withstand regulatory scrutiny? Will payers reimburse?
17. Clinical Validation/Diagnostic Performance
Consider the business and regulatory needs
Engage agency prior to initiating study
Clarify intended use
Identify a reference (gold) standard
Consistent with practice
Recognized by community/literature
Enroll subjects that represent target patients
Select sites that support intended use
Pre-specify
Sample collection/handling procedures
Analysis methods
Use of archived samples (if needed)
October 27, 2014 Lyssa Friedman 17
18. Clinical Outcomes
Clinical Utility
• Patient outcome based on test use and
results
• Randomized control trial
• Changes in physician behavior
October 27, 2014 Lyssa Friedman 18
Study
design
What difference does it make to patient outcomes?
What difference does it make to healthcare costs?
19. Clinical Outcomes/Clinical Utility
Consider the payer
Consider the patient
Effect on patient outcomes
Ethics of randomized controlled trial
when marketed test available
Effect on healthcare costs
October 27, 2014 Lyssa Friedman 19
21. 21
• ACCE Evaluation Process for
Genetic Testing
• Analytic validity
• Clinical validity
• Clinical utility
• Ethical/legal/social
• Publications in these areas
build the reimbursement case
Centers for Disease Control (CDC) Office of Public Health Genomics
Evaluation of Genomic Applications in Practice and Prevention (EGAPP™) Initiative
Publication strategy
October 27, 2014 Lyssa Friedman
23. FDA regulation of LDTs
October 27, 2014 Lyssa Friedman 23
IVD LDT
• CLIA (if LDT)
• FDA
• CLIA
• Physician adoption
• Reimbursement
• FDA
• Physician adoption
• Reimbursement
• Quality system
• SOPs
• Quality for CLIA
• SOPs
• Physician adoption
• Economic modeling
• Clinical utility studies
• FDA
• Physician adoption
• Economic modeling
• Clinical utility studies
Analytic validation
Clinical validation
Documentation
Intended use
24. Keep doing what you’re doing well
Well-designed studies
Clean samples and clinical annotation
Clearly defined gold standard
SOPs and pre-specified protocols
Culture of design review
October 27, 2014 Lyssa Friedman 24
26. Site Selection
What are the goals?
Study completion
Accrual numbers
Adherence to Good Clinical Practices
Pristine samples
Verifiable data
Strategic relationship building
October 27, 2014 Lyssa Friedman 26
Key opinion
leader
Collaborator Influencer
Geographic
significance
27. Case Study
• 142 genes, microarray
• Gold standard: histopathology (central panel)
• Optimized for sensitivity/NPV – safe to avoid surgery
• Company launched 2008 (IVDMIA) – design control implemented
• Product launched as LDT 2011
• Key publications
– 2010: first clinical validation
– 2011: economic model/cost effectiveness (replacement for surgery)
– 2012: second clinical validation, clinical utility (change in recommendation for
surgery)
– 2013: second clinical utility, limits of gold standard
October 27, 2014 Lyssa Friedman 27
Thyroid
nodule
Fine needle
aspirate
biopsy
Cytology
Indeterminate
15-30%
Diagnostic
surgery
Benign >50%
Afirma GEC
94% NPV
28. Case Study: Success/Challenges
Things that worked
• Funded on business plan – agnostic
regarding clinical platform
• All-hands focus on rapid first product
to market
• Aggressive publication plan – never
missed an abstract deadline!
• Small niche market – close
relationship with major KOLs and
influencers, who were clinical sites,
early customers, authors/speakers
• “Boutique” approach to managing
clinical sites, even if challenging
• Two clinical validation studies using
one amended clinical sample
collection protocol
• IVDMIA era – design control
Lessons learned
• “Tarnished” gold standard required
publication, customer education
• NPV as key message – refuted
based on practice variations in
malignancy prevalence
significantly
October 27, 2014 Lyssa Friedman 28
29. What does success look like?
Design a business plan that drives R&D and product development
Build early relationships with KOLs and influencers
Strategize cross-functionally from the beginning
Stick to a long-term strategic publication plan
Commit to a quality system (LDTs)
Create a culture of design review with external reviewers (LDTs)
Adhere to a milestone-based plan aligned with corporate goals
Maintain relationships with strategic sites – even if challenging
Never miss an abstract submission deadline
Partner with marketing/sales group to transition sites to early customers
October 27, 2014 Lyssa Friedman 29
30. What are lessons learned?
Be willing to change thinking quickly and flexibly
Challenge market research assumptions when
clinical operations offers counter-intel
Don’t underestimate the competition and the
naysayers
Stress test the product messaging with regard to
test performance
October 27, 2014 Lyssa Friedman 30
As VP clinical operations at Veracyte, I helped bring the company’s beachhead product to market
As an independent consultant, I help early-stage diagnostic companies design a roadmap for the product development lifecycle. This includes developing reimbursement and publication strategies, and designing studies to help achieve goals quickly and efficiently.
The companies I work with have developed or are developing LDTs, and we are navigating the shifting landscape regarding FDA oversight of LDTs
My point of view is supporting startup LDTs who have traditionally been regulated under CLIA only, and for the most part my comments are focused on a US market
HDE: Humanitarian Device Exemption
example: urine test
Needed:
SOPs
pre-specified protocols and plans
Recommend culture of design or phase review – avoid drinking the Kool-aid
Keep doing what you’re doing well
Clinical and medical affairs milestones that tracked both cross-functionally and upward to company goals
Clinical operations guiding principles:
Clinical operations is the brand
These sites will be our customers in about 5 minutes
Handheld strategic sites to maximize their success
Anticipate what others will say and publish about the space
Veracyte based marketing on high NPV, which had very high number. This was in an environment where clinicians assumed the gold standard, histopathology, was 100%, though our data showed (and was later published) that pathology concordance was 96-97% This was criticized at meetings and in publications as being too dependent on disease prevalence in specific clinical environment. perhaps a sensitivity message could have had more sustained power, despite the fact that it was slightly lower (92%)